Biotech M&A vs. IPOs: How Cash-Rich Big Pharma is Reshaping Sector Valuations
The Dual Forces Shaping the Biotech Sector The biotechnology and biopharma industries are witnessing a critical tug-of-war between public equity markets and private acquisitions. As the sector attempts a tentative IPO (Initial Public Offering) revival, it faces intense competition from cash-rich Big Pharma companies seeking strategic acquisitions. This dynamic is fundamentally altering how early-stage drug … Read more



